An indirect comparison of immunotherapies among patients with locally advanced or metastatic NSCLC with PD-L1 expression ⩾50% who had not received prior systemic therapy for their locally advanced or metastatic disease was recently published.76 Majem et al. assessed OS and PFS with a constant HR NMA using generalized pairwise modeling framework with the Bucher method, which ignored the nonproportionality observed in the survival data. Here, CD274 is linked to metastatic neoplasm.